Ferritin as a novel predictive index for nasopharyngeal carcinoma survival and therapeutic efficacy of different chemotherapy regimens

Table 2 Chemotherapy regimens and laboratory indicator between survivors and non-survivors after treatment

Variable	Total (n = 1142)	Survivors (n = 615)	P (vs pre-treatment)	Non-survivors (n = 527)	P (vs pre-treatment)	Statistic	P (survivors vs non-survivors)
TAM	90.30 ± 13.46	91.48 ± 13.35	0.587	88.69 ± 13.59	0.561	t = -1.09	0.278
TSGF	58.64 ± 18.46	57.93 ± 19.17	0.739	59.45 ± 17.62	0.164	t = 0.99	0.325
AST	22.91 ± 11.72	23.08 ± 11.34	0.732	22.71 ± 12.17	0.819	t = -0.40	0.689
ALT	24.48 ± 23.25	25.35 ± 25.70	0.433	23.49 ± 20.04	0.610	t = -1.02	0.309
ALP	69.73 ± 21.94	69.66 ± 20.91	0.577	69.81 ± 23.10	0.778	t = 0.08	0.936
LDH	165.50 ± 39.74	164.23 ± 36.81	0.058	166.94 ± 42.84	0.970	t = 0.82	0.411
GGT	29.74 ± 29.49	30.14 ± 27.92	0.187	29.29 ± 31.22	0.899	t = -0.35	0.729
5-NT	5.32 ± 4.45	5.04 ± 3.91	0.639	5.63 ± 4.98	0.136	t = 1.59	0.113
GPDA	61.76 ± 18.61	61.99 ± 18.50	0.785	61.51 ± 18.78	0.773	t = -0.31	0.759
ADA	14.50 ± 16.11	14.35 ± 20.03	0.516	14.68 ± 9.95	0.929	t = 0.24	0.809
MAO	4.21 ± 2.47	4.15 ± 2.55	0.801	4.28 ± 2.38	0.856	t = 0.59	0.552
NSE	2.76 ± 1.91	2.78 ± 1.87	0.875	2.74 ± 1.96	0.772	t = -0.24	0.812
CEA	1.74 ± 6.55	1.41 ± 1.10	0.054	2.16 ± 9.71	0.275	t = 1.24	0.215
FERITIN	94.80 ± 78.43	59.86 ± 31.90	< 0.001a	138.57 ± 95.67	< 0.001a	t = 11.43	< 0.001a
AFP	2.43 ± 5.28	2.32 ± 3.18	0.658	2.57 ± 7.08	0.666	t = 0.52	0.604
Treatment, (%)						-	0.5701
CAV	0.10	0.19		0.00
CNF	0.10	0.00		0.21
DF	0.10	0.19		0.00
DGP	0.10	0.19		0.00
DN	7.98	7.41		8.61
DNF	0.50	0.38		0.63
DNL	0.10	0.19		0.00
DP	4.49	3.80		5.25
DPF	1.50	1.52		1.47
DPN	0.10	0.19		0.00
DPS	0.10	0.19		0.00
GN	0.40	0.38		0.42
GP	0.60	0.76		0.42
NF	16.17	16.35		15.97
NP	0.10	0.19		0.00
NPF	0.50	0.57		0.42
PF	12.87	10.08		15.97
TDP	0.20	0.19		0.21
TF	0.10	0.19		0.00
TN	16.07	16.16		15.97
TNF	2.30	2.66		1.89
TP	18.96	19.77		18.07
TPF	1.80	2.09		1.47
TPN	0.10	0.00		0.21
Radiotherapy	13.17	14.45		11.76
Radiotherapy plus chemotherapy	0.90	1.14		0.63
Surgery	0.10	0.00		0.21
Surgery plus radiotherapy	0.50	0.76		0.21

¹Simulated P value.

^aP < 0.05.

t: T-test, Fisher’s exact test. TAM: Tumor-associated material; TSGF: Tumor-supplied group of factors; NSE: Neuron-specific enolase; CEA: Carcinoembryonic antigen; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase; GGT: Gamma-glutamyl transferase; 5-NT: 5'-Nucleotidase; GPDA: Glycyl-proline-dipeptidyl aminopeptidase; ADA: Adenosine deaminase; MAO: Monoamine oxidase; CAV: Cyclophosphamide, doxorubicin plus etoposide; CNF: Cyclophosphamide, nidaplatin plus 5-FU; DF: Docetaxel plus 5-FU; DGP: Docetaxel, gemcitabine plus cisplatin; DN: Docetaxel plus nedaplatin; DNF: Docetaxel, nidaplatin plus 5-FU; DNL: Docetaxel, nidaplatin plus leucovorin; DP: Docetaxel plus cisplatin; DPF: Docetaxel, cisplatin plus 5-FU; DPN: Docetaxel, cisplatin plus nedaplatin; DPS: Docetaxel, cisplatin plus teysuno; GN: Gemcitabine plus nedaplatin; GP: Gemcitabine plus cisplatin; NF: Nidaplatin plus 5-FU; NP: Nidaplatin plus cisplatin; NPF: Nidaplatin, cisplatin plus 5-FU; PF: Cisplatin plus 5-FU; TDP: Taxol, docetaxel plus cisplatin; TF: Taxol, plus 5-FU; TN: Taxol plus nedaplatin; TNF: Taxol, nidaplatin plus 5-FU; TP: Taxol plus cisplatin; TPF: Taxol, cisplatin plus 5-FU; TPN: Taxol, cisplatin plus nedaplatin.